Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
ENGAGER-PSMA-01 is a first-in-human, open-label, multicenter Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 administered as monotherapy or in combination in adult patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
In December 2024, Janux reported positive interim clinical data from the Phase 1a dose escalation portion of the trial in 16 mCRPC patients with a median of four prior lines of therapy. At that time, the median radiographic progression-free survival (rPFS) reported was 7.4 months for all 16 patients.* As of April 21, 2025, updated results** have been achieved in the same 16 patients supporting the initiation of the Phase 1b expansion studies:
Median rPFS of 7.5 months (n=16)
Median rPFS of 7.9 months for patients treated at 6mg and 9mg target doses (n=9)
6-month rPFS of 65% (n=16)
6-month rPFS of 78% for patients treated at 6mg and 9mg target doses (n=9)
Safety data remained consistent with the December 2024 data disclosure (n=16)
*8/16 patients were noted as in-progress in the December 2024 reported results.
**rPFS results based upon Kaplan-Meier estimate.
In addition, Janux has selected a CRS-mitigation strategy to support the initiation of the Phase 1b expansion studies that is designed to maintain the CRS profile reported in December.
The first Phase 1b expansion study will enroll taxane-naïve mCRPC patients and is designed to generate additional safety and efficacy data in this first and second line (1L/2L) patient population. This study will assess JANX007 monotherapy at two dose regimens (0.3/2/6mg and 0.3/2/9mg) with dosing administered once weekly or once every two weeks in mCRPC patients who have progressed on or after novel hormonal therapy (NHT).
'Initiation of the taxane-naïve study marks an important step as we begin to evaluate JANX007 in earlier-line mCRPC patient populations,' said Zachariah McIver, D.O., Ph.D., Chief Medical Officer of Janux. 'While therapeutic options for mCRPC have expanded, there remains a significant need for novel, non-chemotherapeutic approaches.'
Janux plans to initiate three additional Phase 1b expansion studies, evaluating:
JANX007 in combination with an androgen receptor inhibitor in taxane-experienced mCRPC patients
JANX007 monotherapy in PARP inhibitor-resistant mCRPC patients
JANX007 monotherapy in NHT- and taxane-experienced mCRPC patients designed to support OPTIMUS dose selection for registrational studies
'Improved efficacy and durability of responses has been observed by other prostate cancer drugs and TCEs when moving into earlier lines of therapy. There are also indications that safety with TCEs improve in earlier lines of therapy where disease burden is lower. We believe that these observations, coupled with the data seen in our Phase 1a dose escalation in later line patients, strongly support our decision to develop JANX007 in earlier lines of therapy,' said David Campbell, Ph.D., President and CEO of Janux.
Additional data from JANX007 and JANX008 will be presented at future Janux events in the second half of 2025. Separately, Janux will host an R&D Day in mid-2025 highlighting product candidates identified from its preclinical pipeline to move into clinical trials.
Janux's TRACTr and TRACIr Pipeline
Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer. Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux's proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned preclinical studies and clinical trials, the timing of and plans for regulatory filings, the potential benefits of Janux's product candidates and platform technologies, the timing of future data releases, and expectations regarding the use of Janux's platform technologies to generate novel product candidates. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, the risks related to geopolitical events, including international tariffs, global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to Janux's business operations and development activities, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Ondas Holdings Inc (ONDS) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ondas Holdings Inc (NASDAQ:ONDS) reported record quarterly revenue of $6.3 million, a more than sixfold increase over the same period last year. The company reaffirmed its full-year revenue target of at least $25 million for 2025, with more than $20 million expected from its OAS business unit. Ondas Holdings Inc (NASDAQ:ONDS) has a strong balance sheet with $68.6 million in cash and no holding company debt, providing financial flexibility for growth. The company has secured over $39 million in orders in the last 12 months, with a backlog growing to $22 million at the end of Q2 2025. Ondas Holdings Inc (NASDAQ:ONDS) is expanding its footprint in defense and homeland security markets, with significant orders from Europe, Asia, and the United States. Negative Points Operating expenses increased to $12.6 million in Q2 2025, up from $8.1 million in Q2 2024, primarily due to higher human resource costs. The company reported an operating loss of $9.2 million in Q2 2025, compared to $8.3 million in Q2 2024. Ondas Holdings Inc (NASDAQ:ONDS) is still in the early stages of platform adoption, with revenues not yet covering operating expenses. Gross margins can be volatile due to early stages of platform adoption and shifts in revenue mix. The company faces uncertainty around the timing of customer activity, which could affect revenue fluctuations from quarter to quarter. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with ONDS. Q: Can you provide more details on the $23 million plus of bookings and the source of this confidence? A: Eric Brock, Chairman and CEO, explained that the bookings are driven by a combination of new customer acquisitions and the expansion of existing programs. The company is capturing new customers with proof-of-concept orders and aims to expand these into larger infrastructure build-outs. The pipeline includes potential orders in the tens of millions of dollars, suggesting that the guidance might be conservative. Q: Are the two control acquisitions in addition to the recent small acquisition, and will they contribute to revenue? A: Eric Brock confirmed that the two control acquisitions are in addition to the recent transactions with Zickle and Rift. These acquisitions are expected to be revenue-generating and will contribute to the company's growth. Q: Is the current gross margin a good reflection of the OAS business at scale? A: Eric Brock stated that while the current gross margin is a good target, there is potential for improvement through increased volume and design for manufacturing. However, he cautioned that margins might be volatile until the business reaches scale. Q: How do the two acquisitions tie in with the 2026 revenue target, and were they included in the original forecast? A: Eric Brock clarified that the 2026 revenue target of $40 million for OAS was entirely organic. The acquisitions will be accretive to both the 2025 and 2026 outlooks. Q: Can you provide more details on the Kestrel win with the Urban Public Safety Agency? A: Eric Brock explained that the Kestrel system is an airspace awareness tool, primarily bundled with the Optimus infrastructure. The demand for counter-UAS technologies is growing, and the Kestrel system is part of the initial detection layer. The company sees potential for further engagement with this customer. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14 minutes ago
- Business Wire
Spartan Emergency Response Breaks Ground on $20 Million Facility Expansion to Increase Production
BRANDON, S.D.--(BUSINESS WIRE)-- Spartan Emergency Response, a brand of REV Group Inc. subsidiary Spartan Fire LLC and a leading manufacturer of fire apparatus, broke ground on a facility expansion today with South Dakota Governor Larry Rhoden offering his support. This comes after REV Group announced a $20 million investment in the facility during its second-quarter earnings call on June 4. The investment marks a major milestone in efforts to increase production capacity by 40% for its fully custom Spartan Emergency Response apparatus as well as its high-performance, semi-custom fire trucks that can be completed and delivered in under a year. Share The investment marks a major milestone in efforts to increase production capacity by 40% for its fully custom Spartan Emergency Response apparatus as well as its high-performance, semi-custom fire trucks that can be completed and delivered in under a year. The expansion will also increase the facility's painting and fabrication process capabilities across the Brandon campus. 'We are delighted to host our groundbreaking ceremony today to announce our plans for expansion. This investment will double our manufacturing footprint and help us meet the rising demand from fire departments across the nation by allowing us to build more fire apparatus and deliver it faster,' said Mike Virnig, President, REV Specialty Vehicles Segment. The expansion will also bring lasting economic benefits to the Brandon and Sioux Falls region: Creation of 50 new jobs, with an estimated $1.8 million increase in annual payroll Estimated $85,000 increase in annual property tax contributions Addition of 56,000 square feet to the existing facility 'Thank you to Spartan Emergency Response for your heart of service and for your heart to provide a quality product to protect people and to serve people which in most cases is on their worst day,' said South Dakota Gov. Rhoden during the groundbreaking presentation, who also shared his service as a volunteer firefighter. Other officials and guests who attended included: South Dakota Lieutenant Governor Tony Venhuizen City of Brandon Mayor Harry Buck Chad Krier, Constituent Services Representative at the Office of United States Senator Mike Rounds Benjamin Ready, Southeast Regional Director from the Office of United States Senator John Thune Landon Hanson, Military and Veteran Services Representative for Congressman Dusty Johnson For more information about Spartan Emergency Response, please visit About Spartan Emergency Response Spartan Emergency Response, comprised of REV Group, Inc. (NYSE: REVG) subsidiaries Spartan Fire, LLC, Smeal SFA, LLC, Smeal LTC, LLC and Smeal Holding, LLC, is a North American leader in the emergency response market and offers brands including Spartan Authorized Parts, Spartan Factory Service Centers, Spartan Fire Chassis, Smeal, and Ladder Tower. Spartan Emergency Response vehicles are well known for safety, quality, durability, aftermarket product support, and first-to-market innovation. The company operates facilities in Michigan, Pennsylvania, South Dakota, and Nebraska. About REV Group, Inc. REV Group companies are leading designers and manufacturers of specialty vehicles and related aftermarket parts and services, which serve a diversified customer base, primarily in the United States, through two segments: Specialty Vehicles and Recreational Vehicles. The Specialty Vehicles Segment provides customized vehicle solutions for applications, including essential needs for public services (ambulances and fire apparatus) and commercial infrastructure (terminal trucks and industrial sweepers). REV Group's Recreational Vehicles Segment manufactures a variety of RVs from Class B vans to Class A motorhomes. REV Group's portfolio is made up of well-established principal vehicle brands, including many of the most recognizable names within their industry. Several of REV Group's brands pioneered their specialty vehicle product categories and date back more than 50 years. REV Group trades on the NYSE under the symbol REVG. Investors-REVG
Business Wire
14 minutes ago
- Business Wire
Alliance Resource Partners, L.P. Announces the Promotion of Jesse M. Parrish to Sr. Vice President and Chief Commercial Officer of Alliance Coal, LLC
TULSA, Okla.--(BUSINESS WIRE)--Alliance Resource Partners, L.P. (NASDAQ: ARLP) is pleased to announce the promotion of Jesse M. Parrish to Sr. Vice President and Chief Commercial Officer of ARLP's subsidiary, Alliance Coal, LLC ('Alliance Coal'), effective immediately. In Mr. Parrish's expanded role, he will oversee Alliance Coal's commercial strategy including oversight of the sales, marketing, and logistics functions as well as its government relation functions. Mr. Parrish will continue to report to Joseph W. Craft III, President and Chief Executive Officer of Alliance Coal and ARLP. Mr. Craft explained, 'Jesse's expanded role is a natural evolution of our vision for him as he assumes more of my day-to-day responsibilities allowing me more time to focus on strategic growth opportunities for ARLP. President Trump has declared his administration will do whatever it takes to ensure that the United States can build and maintain the largest, most powerful and most advanced AI infrastructure anywhere on the planet. To achieve global AI dominance, America has to maintain, extend and expand the current electric generating assets and invest significantly in new generation infrastructure. ARLP's aim is to pursue opportunities in the growing power infrastructure sector and preserve our nation's coal fleet.' Mr. Parrish joined Alliance Coal in April 2025 as Senior Vice President of Operations and previously spent over a decade in different senior capacities in the eastern U.S. coal industry. Timothy J. Whelan's role as Sr. Vice President of Sales and Marketing, will remain unchanged, and he and his team remain the primary contact for Alliance Coal's customers and other commercial partners. About Alliance Resource Partners, L.P. ARLP is a diversified energy company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy and related infrastructure. News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission ('SEC'), are available at For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@
